Owlstone secures $6.5M for breath-based diagnostics for infectious disease
Owlstone Medical has secured a $5 million equity investment and initial $1.5 million grant funding, committed by the Bill and Melinda Gates Foundation, for development of breath-based diagnostic solutions to improve outcomes in the developing world.
Continue Reading
ETH develops AI algorithm for drug discovery based on 3D protein surface
Chemists at ETH Zurich have developed a new computer process that enables the generation of active pharmaceutical ingredients at speed, based on a protein’s three-dimensional surface.
Continue Reading
Moderna banks on OpenAI to accelerate mRNA research
In an ambitious move, Moderna has teamed up with OpenAI, the artificial intelligence company behind ChatGPT, to further integrate generative AI (GenAI) across its mRNA drug development and manufacturing operations.
Continue ReadingPopular News
Endeavor raises $132.5m for fibrosis, cancer drugs
Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fibrosis and solid tumours.
Alzheimer’s drug Leqembi moves forward, still in low gear
Biogen has given an update on the rollout of its Eisai-partnered Alzheimer’s disease therapy Leqembi alongside its first-quarter results, showing that while the drug’s take-up is building, it remains slow going. In-market sales were $19 million in the quarter, up from